Discipline | Oncology |
---|---|
Language | English |
Edited by | Patricia A. Ganz |
Publication details | |
History | 1940–present |
Publisher | |
Frequency | Monthly |
10.3 (2022) | |
Standard abbreviations | |
ISO 4 | J. Natl. Cancer Inst. |
Indexing | |
CODEN | JNCIEQ |
ISSN | 0027-8874 (print) 1460-2105 (web) |
OCLC no. | 01064763 |
Links | |
Discipline | Oncology |
---|---|
Language | English |
Edited by | Dr. Patricia Ganz |
Publication details | |
History | 1959–present |
Publisher | |
Standard abbreviations | |
ISO 4 | JNCI Monogr. |
Indexing | |
ISSN | 1052-6773 (print) 1745-6614 (web) |
LCCN | 94660018 |
OCLC no. | 21986096 |
Links | |
The Journal of the National Cancer Institute (JNCI) is a peer-reviewed medical journal covering research in oncology that was established in August 1940. It is published monthly by Oxford University Press and is edited by Patricia A. Ganz. It was merged with Cancer Treatment Reports in January 1988. JNCI used to be the official journal of the U.S. National Cancer Institute (NCI); however, in 1996, the NCI and JNCI agreed to grow apart. Over the next five years, JNCI became independent of the NCI.
A related publication is Journal of the National Cancer Institute Monographs (JNCI Monographs), established in 1959, which publishes manuscripts from cancer and cancer-related conferences, as well as groups of papers on specific subjects related to cancer. In January 1986, Cancer Treatment Symposia was merged with JNCI Monographs. Additionally, JNCI Cancer Spectrum (JNCI CS) is a fully open access journal, which was established in 2017. It is published bimonthly by Oxford University Press and is edited by Ronald Chen.
The history of JNCI is linked to that several other journals. A full history of JNCI and JNCI Monographs is presented below.
JNCI is indexed and abstracted in:
According to the Journal Citation Reports , the journal has a 2014 impact factor of 12.583, ranking it 8th out of 211 journals in the category "Oncology". [13]
JNCI Monographs is indexed and abstracted in
Chemotherapy is a type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent or it may aim to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.
Non-Hodgkin lymphoma (NHL), also known as non-Hodgkin's lymphoma, is a group of blood cancers that includes all types of lymphomas except Hodgkin lymphomas. Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and tiredness. Other symptoms may include bone pain, chest pain, or itchiness. Some forms are slow-growing while others are fast-growing.
The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.
Vincent Theodore DeVita Jr. is the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, and a Professor of Epidemiology and Public Health. He directed the Yale Cancer Center from 1993 to 2003. He has been president of the American Cancer Society (2012-2013). He is internationally recognized as a pioneer in the field of oncology for his work on combination-chemotherapy treatments.
Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..
Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. DCIS is classified as Stage 0. It rarely produces symptoms or a breast lump one can feel, typically being detected through screening mammography. It has been diagnosed in a significant percentage of men.
Cancer and Leukemia Group B is a cancer research cooperative group in the United States.
Gynecologic oncology is a specialized field of medicine that focuses on cancers of the female reproductive system, including ovarian cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer. As specialists, they have extensive training in the diagnosis and treatment of these cancers.
John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.
Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of tumors. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:
Joseph W. Cullen was an American cancer prevention and rehabilitation researcher and briefly director of the AMC Cancer Research Center (1989-1990). He previously worked at the VA Hospital in Maryland (1968-1973), the National Institutes of Health (1973), the National Cancer Institute (NCI), and the Jonsson Comprehensive Cancer Center (1976-1982), holding high-level positions such as division director at several. He was a coordinator, creator, and researcher for the Smoking Tobacco and Cancer Program at the NCI, the largest anti-smoking campaign in the world at that time. Cullen wrote more than 90 publications in his lifetime, including four books.
Cancer is a biweekly peer-reviewed scientific journal covering oncology. The journal was established in 1948. It is an official journal of the American Cancer Society and is published by Wiley-Blackwell on behalf of the society. The first editor-in-chief was Fred W. Stewart, who held that position until 1961. The current editor-in-chief is Suresh S. Ramalingam, and the previous one was Fadlo R. Khuri. Cancer Cytopathology was published as a section from 1997 until 2008, when it was split into a separate journal.
The Office of Cancer Complementary and Alternative Medicine (OCCAM) is an office of the National Cancer Institute (NCI) in the Division of Cancer Treatment and Diagnosis. OCCAM was founded in 1998 and is responsible for NCI's research agenda in pseudoscientific complementary and alternative medicine (CAM), as it relates to cancer prevention, diagnosis, treatment, and symptom management. The OCCAM differs from the National Center for Complementary and Integrative Health in that it is exclusively focused on cancer, while the NCCIH funds a much broader program of NIH research into CAM for all diseases and disorders. It last produced an annual report in 2011 and spent $105 million on CAM research in 2011.
Peritoneal mesothelioma is the name given to the cancer that attacks the lining of the abdomen. This type of cancer affects the lining that protects the contents of the abdomen and which also provides a lubricating fluid to enable the organs to move and work properly.
William Douglas Figg is an American scientist (pharmacologist). He is a senior investigator (tenured) at the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland. He holds multiple titles within the NCI: Associate Director of the Center for Cancer Research, Co-Director of the Office of Translational Resources, Acting Branch Chief for the Genitourinary Malignancies Branch, Chief of the Clinical Pharmacology Program, and head of the Molecular Pharmacology Section. Dr. Figg is also the Co-Chief of Basic Research at the Center for Prostate Disease Research within the Walter Reed National Military Medical Center – Murtha Cancer Center in Bethesda, Maryland.
High-dose chemotherapy and bone marrow transplant (HDC/BMT), also high-dose chemotherapy with autologous bone marrow transplant, was an ineffective treatment regimen for metastatic breast cancer, and later high-risk breast cancer, that was considered promising during the 1980s and 1990s. With an overall idea that more is better, this process involved taking cells from the person's bone marrow to store in a lab, then to give such high doses of chemotherapy drugs that the remaining bone marrow was destroyed, and then to inject the cells taken earlier back into the body as replacement. It was ultimately determined to be no more effective than normal treatment, and to have significantly higher side effects, including treatment-related death.
Expert Review of Pharmacoeconomics & Outcomes Research is a bimonthly peer-reviewed medical journal covering all aspects of pharmacoeconomics. It was established in 2001 and is published by Informa. The editor-in-chief is A. Bottomley.
Patricia Anne Ganz is an American medical oncologist. She is a professor of health policy and management in the Fielding School of Public Health and a professor of medicine in the David Geffen School of Medicine at UCLA. In 2007, she was elected to the Institute of Medicine.
Angela Bacelar Mariotto is a statistician who researches the development and improvement of cancer progress measures. She is chief of the data analytics branch at the National Cancer Institute. Mariotto was a researcher at the Istituto Superiore di Sanità.